{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:07:58Z","timestamp":1788984478731,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.urolonc.2024.01.300","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T17:22:28Z","timestamp":1713806548000},"page":"245.e19-245.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center"],"prefix":"10.1016","volume":"42","author":[{"given":"Lucas","family":"Kastner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3993-7974","authenticated-orcid":false,"given":"Constantin","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schmautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Storz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.01.300_bib0001","unstructured":"World Health Organization. Bladder cancer; 2023. Available under: https:\/\/www.iarc.who.int\/cancer-type\/bladder-cancer\/#pressrelease."},{"key":"10.1016\/j.urolonc.2024.01.300_bib0002","unstructured":"European Association of Urology. EAU guidelines, Non-muscle-invasive Bladder Cancer. Available under: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer."},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.300_bib0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.300_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0305-7372(79)80043-2","article-title":"Hyperthermia in the treatment of cancer","volume":"6","author":"Field","year":"1979","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.urolonc.2024.01.300_bib0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.20517\/2394-4722.2017.35","article-title":"Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery","volume":"3","author":"Yagawa","year":"2017","journal-title":"JCMT"},{"key":"10.1016\/j.urolonc.2024.01.300_bib0006","doi-asserted-by":"crossref","unstructured":"Chiancone F, Fabiano M, Carrino M, Fedelini M, Meccariello C, Fedelini P. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette\u2013Gu\u00e9rin failure. Arab J Urol; 19(1):86\u201391. https:\/\/doi.org\/10.1080\/2090598X.2021.1874627.","DOI":"10.1080\/2090598X.2021.1874627"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.300_bib0007","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.300_bib0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2024.01.300_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) Using Mitomycin-C in patients with non-muscle invasive bladder cancer in spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.300_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3233\/BLC-220026","article-title":"A multicenter study of 2-year outcomes following hyperthermia therapy with Mitomycin C in treating non-muscle invasive bladder cancer: HIVEC-E","volume":"8","author":"Tan","year":"2022","journal-title":"BLC"},{"issue":"3 Pt 2","key":"10.1016\/j.urolonc.2024.01.300_bib0011","first-page":"959","article-title":"A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.300_bib0012","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.300_bib0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ucl.2019.09.008","article-title":"Heated intravesical chemotherapy: biology and clinical utility","volume":"47","author":"Tan","year":"2020","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.300_bib0014","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of tar-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.01.300_bib0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.300_bib0016","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.01.300_bib0017","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.01.300_bib0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2023.41.6_suppl.503","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non\u2013muscle-invasive bladder cancer (HR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: cohort 2 interim analysis results","volume":"41","author":"Catto","year":"2023","journal-title":"JCO"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T02:07:06Z","timestamp":1717294026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924003405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1078143924003405"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.300","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}